High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients

BACKGROUND/AIMS: Patients with genotype 3 hepatitis C virus (G3-HCV) cirrhosis are very difficult to treat compared to patients with other HCV genotypes. The optimal treatment duration and drug regimen associated with ribavirin (RBV) remain unclear. To evaluate the efficacy and safety of daclatasvir...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Gut Liver
Главные авторы: Pellicelli, Adriano, Messina, Vincenzo, Giannelli, Valerio, Distefano, Marco, Palitti, Valeria Pace, Vignally, Pascal, Tarquini, Pierluigi, Izzi, Antonio, Moretti, Alessandra, Babudieri, Sergio, Dell’Isola, Serena, Marignani, Massimo, Scifo, Gaetano, Iovinella, Vincenzo, Cariti, Giuseppe, Pompili, Maurizio, Candilo, Francesco Di, Fontanella, Luca, Ettorre, Giuseppe M., Vennarecci, Giovanni, Ippolito, Antonio Massimo, Barbarini, Giorgio
Формат: Artigo
Язык:Inglês
Опубликовано: Editorial Office of Gut and Liver 2020
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7234881/
https://ncbi.nlm.nih.gov/pubmed/30970444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5009/gnl18269
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы